检索结果 - Muhammad I. Rehman

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    CD8αβ T Cells Are Not Essential to the Pathogenesis of Arthritis or Colitis in HLA-B27 Transgenic Rats

    CD8αβ T Cells Are Not Essential to the Pathogenesis of Arthritis or Colitis in HLA-B27 Transgenic Rats 由 Ekkehard May, Martha L. Dorris, Nimman Satumtira, Imran Iqbal, Muhammad I. Rehman, Ellis Lightfoot, Joel D. Taurog

    出版 2003
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

    Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or C... 由 Stanley Cohen, S. Radominski, Hideto Kameda, Alan Kivitz, Michael Tee, Carol Cronenberger, Min Zhang, Sarah Hackley, Muhammad I. Rehman, Oliver von Richter, Rieke Alten

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis

    A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis 由 Hideto Kameda, Eishi Uechi, Tatsuya Atsumi, Carlos Abud‐Mendoza, Kazumasa Kamei, Tsugumi Matsumoto, Darío Ponce de León, Muhammad I. Rehman, Min Zhang, S. Radominski

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

    A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthrit... 由 Stanley Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, S. Radominski, Muhammad I. Rehman, Ramesh Palaparthy, Karl Schumacher, Susanne Schmitt, Steven Y. Hua, Claudia Ianos, K. Lea Sewell

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: